A genetic second check makes newborn SCID screening far more accurate

The problem

Newborn screening for severe combined immunodeficiency (SCID) — the serious inherited condition that leaves babies with almost no immune defence — works by measuring a marker called TRECs (T-cell receptor excision circles) on the routine heel-prick blood spot. It rarely misses a truly affected baby, but it flags many babies who turn out to be healthy. Each false alarm means anxious parents, extra hospital visits, and cost.

What they did

Researchers added targeted next-generation sequencing (NGS) as a "second-tier" test, run on the same dried blood spot, for 68 newborns already referred by TREC screening, and linked the results to long-term follow-up. A built-in safety-net rule immediately referred any baby with profoundly low TRECs, so sensitivity for real SCID stayed high.

What they found

• The genetic second check raised the screening's positive predictive value from 22% to 55% — roughly halving the false alarms.
• This was achieved without missing babies with severe immune disease.
• The main trade-off — not flagging some milder T-cell abnormalities that have no genetic cause — was judged to have limited clinical impact.

Why it matters

This is a concrete, everyday example of genomics improving an existing routine pathway rather than replacing it: a targeted genetic test bolted onto standard screening spares families needless worry and the system needless work, while keeping the safety of the original test. For neonatal and paediatric teams who field these referrals and support the families, it's a preview of how genomic testing is quietly entering frontline care.